5 Key Sessions at the American Association of Psychiatric Pharmacists Annual Meeting 2024

Pharmacy Times® will be covering the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting from April 7 to April 10, 2024. AAPP’s annual meeting brings together mental health professionals with a focus on psychiatric pharmacotherapy, including 24+ hours of Accreditation Council for Pharmacy Education-approved programming, according to the conference website. There will be a welcome and reception event, opportunities for networking, peer-to-peer idea exchange, and more.

Image Credit: aphotostory -stock.adobe.com

Stay tuned on pharmacytimes.com for exclusive session coverage and interviews with presenters, such as:

• A presentation focused on social determinants of health (SDOH) in the treatment of depression. It will include how SDOH can affect the treatment and care of mental health conditions as well as how sometimes patient’s social challenges could be overlooked.There will be a focus on how pharmacists can understand SDOH and how pharmacists can treat their patients while considering their SDOH factors.
• An interview with Noll Campbell, PharmD, MS, who will discuss the applications of anticholinergic medications in older adults as well as potential negative outcomes. Additionally, the interview will discuss research associated with the long-term use of anticholinergic medications with Alzheimer disease and other dementias.
• An educational session regarding the psychiatric and neurological pipelines. It will include up-to-date information and clinical developments in the pipeline. The session will cover advances in new and emerging psychiatric and neurologic medications and how these agents fit into current clinical practice, including safety and efficacy date and monitoring requirements.
• An interview with Andrew Cutler, MD, who will discuss treating neurocircuitry that affects dopaminergic neurotransmission relating to schizophrenia. Further, the interview ill cover the potential novel agents designed to regulate dopamine levels without affecting dopamine D2 receptors.
• A presentation on the role of cannabis and cannabidiol products to treat anxiety. The session will cover the differences between cannabis, hemp, FDA-approved cannabidiol, and synthetic cannabis as well as the role and safety of these treatments in anxiety disorders. Further, the presentation will focus on literate so pharmacists can apply these findings to their patients with anxiety disorders and how to best educate patients on these products.

Follow Pharmacy Times for coverage of the conference on our website and on social media for the latest updates.